TY - JOUR
T1 - Prostate cancer screening
T2 - What we have learned from the PLCO and ERSPC trials
AU - La Rochelle, Jeffrey
AU - Amling, Christopher L.
PY - 2010/5
Y1 - 2010/5
N2 - Two large randomized trials on prostate cancer screening have recently reported their 10-year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) study found a slightly higher risk of a prostate cancer diagnosis in the screening cohort, but no cancer-specific survival advantage was seen for this group. However, the study had widespread screening contamination in the control arm that significantly weakens the study's ability to reach a valid conclusion about the benefits of screening. The European Randomized Study of Screening in Prostate Cancer (ERSPC) was less affected by screening contamination of the control arm, and a cancer-specific survival benefit for the screening arm was seen by 7-8 years (RR, 0.70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening.
AB - Two large randomized trials on prostate cancer screening have recently reported their 10-year results with somewhat differing conclusions. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) study found a slightly higher risk of a prostate cancer diagnosis in the screening cohort, but no cancer-specific survival advantage was seen for this group. However, the study had widespread screening contamination in the control arm that significantly weakens the study's ability to reach a valid conclusion about the benefits of screening. The European Randomized Study of Screening in Prostate Cancer (ERSPC) was less affected by screening contamination of the control arm, and a cancer-specific survival benefit for the screening arm was seen by 7-8 years (RR, 0.70-0.80). Based on these studies, it is reasonable to conclude that there is a survival benefit for screening, but it may not extend to older men (>75 years) who have undergone prior screening.
KW - Prostate cancer
KW - Prostate-specific antigen
KW - Randomized studies
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=77952236601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952236601&partnerID=8YFLogxK
U2 - 10.1007/s11934-010-0109-5
DO - 10.1007/s11934-010-0109-5
M3 - Short survey
C2 - 20425627
AN - SCOPUS:77952236601
SN - 1527-2737
VL - 11
SP - 198
EP - 201
JO - Current urology reports
JF - Current urology reports
IS - 3
ER -